Skip to main content
. Author manuscript; available in PMC: 2013 Sep 1.
Published in final edited form as: Lancet Oncol. 2012 Aug 15;13(9):906–915. doi: 10.1016/S1470-2045(12)70274-7

Table 1.

Characteristics of the Patients at Diagnosis Rapid Early Response Regimens

Characteristic* Continuous Dexamethasone
# (%), N = 652
Alternate-Week Dexamethasone
# (%), N = 649
P, t

Age, y 0·55
  1 to 9 249 (38·2) 229 (35·3)
  10 to 15 324 (49·7) 336 (51·8)
  16+ 79 (12·1) 84 (12·9)

White cells, × 109/L 0·37
  Less than 50 324 (49·7) 341 (52·5)
  50 to 199 254 (39·0) 248 (38·2)
  200+ 74 (11·3) 60 (9·3)

Sex 0·58
  Male 376 (57·7) 384 (59·2)
  Female 276 (42·3) 265 (40·8)

Race 0·32
  White 454 (70·5) 441 (69·2)
  Black 29 (4·5) 41 (6·4)
  Other 161 (25·0) 155 (24·4)

Liver 0·86
  Normal 204 (46·4) 207 (48·0)
  Moderately enlarged 204 (46·4) 192 (44·5)
  Markedly enlarged 32 (7·2) 32 (7·5)

Spleen 0·85
  Normal 266 (41·1) 271 (42·0)
  Moderately enlarged 311 (48·1) 301 (46·6)
  Markedly enlarged 70 (10·8) 74 (11·4)

Lymph nodes 0·16
  Normal 310 (47·9) 299 (46·3)
  Moderately enlarged 275 (42·4) 300 (46·4)
  Significantly enlarged 63 (9·7) 47 (7·3)

Mediastinal mass 0·74
  Absent 547 (84·5) 541 (83·9)
  Present 100 (15·5) 104 (16·1)

Hemoglobin, g/L 0·72
  10 to 79 286 (45·4) 291 (46·6)
  80 to 110 198 (31·4) 201 (32·1)
  More than 110 146 (23·2) 133 (21·3)

Platelets, × 109/L 0·03
  1 to 49 325 (50·4) 357 (55·4)
  50 to 149 212 (32·9) 211 (32·8)
  150+ 108 (16·7) 76 (11·8)

Immunophenotyping 0·39
  B-cell lineage 439 (77·8) 442 (79·9)
  T-cell lineage 125 (22·2) 111 (20·1)

Karyotypic features
  No. 0·06
  Diploid (46) 111 (31·9) 110 (32·2)
  Pseudodiploid (46) 112 (32·2) 118 (34·5)
  Hypodiploid (less than 46) 25 (7·2) 42 (12·3)
  Hyperdiploid (47 to 50) 48 (13·8) 32 (9·4)
  Hyperdiploid (more than 50) 52 (14·9) 40 (11·7)

Translocations 0·59
  t(4;11) present 7 (2·0) 9 (2·6)
  t(4;11) absent 341 (98·0) 333 (97·4)
  t(1;19) present 14 (4·0) 21 (6·1) 0·21
  t(1;19) absent 334 (96·0) 321 (93·9)

The global χ 2 test for homogeneity was used

— indicates not applicable

*

Because of rounding, not all percentages total 100; percentages were based on the number of patients for whom there were data on the various characteristics

The centrally reviewed and accepted cytogenetic data were available for a subgroup of patients